E. Jung

Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants.

R. Schelonka, S. Hetherington, F. Eyal, 2007, The Journal of pediatrics.

A Urine Preservative System to Maintain Bacterial Counts

R. L. Kaplan, W. Landau, S. Levin, 1985, Clinical pediatrics.

Complement component C9 enhances the capacity of beta-lactam antibiotics to kill Escherichia coli in vitro and in vivo.

R. Feldhoff, B. Walz, H. Lassiter, 1998, The American journal of the medical sciences.

Multicenter Study to Assess Safety and Efficacy of INH-A21, a Donor-Selected Human Staphylococcal Immunoglobulin, for Prevention of Nosocomial Infections in Very Low Birth Weight Infants

D. Kaufman, R. Schelonka, S. Hetherington, 2005, The Pediatric infectious disease journal.

The Administration of Complement Component C9 Enhances the Survival of Neonatal Rats with Escherichia coli Sepsis1

R. Feldhoff, B. Morgan, L. Goldsmith, 1997, Pediatric Research.

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children

G. Losonsky, E. Connor, K. Abarca, 2009, The Pediatric infectious disease journal.